Dr. John E. Mullinax, MD

Dr. Mullinax practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Mullinax's NPI, 1285825661, was assigned on August 9, 2007. Dr. Mullinax graduated from USF Health Morsani College of Medicine in 2007. Dr. Mullinax holds Florida license ME 107440.

Dr. Mullinax's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Mullinax's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Mullinax is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mullinax practices, 2 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Mullinax's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Mullinax is board certified in complex general surgical oncology by the American Board of Surgery. Dr. Mullinax is licensed in Florida.

Dmand AI lists esophagus, stomach, or upper small intestine surgery among the conditions Dr. Mullinax treats.

CMS data shows 41 Medicare services from Dr. Mullinax across 3 procedure codes in 2024, all of them office visits, for 53 Medicare patients. Medicare paid $4,192 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 53 Medicare patients who saw Dr. Mullinax in 2024. The largest group is 65 to 74, with 30 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mullinax's median patient age at 66, with 42% women.

In 2024, Dr. Mullinax wrote 11 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $21 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Mullinax for performance year 2024, reported as part of a group. Dr. Mullinax accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mullinax as offering telehealth.

Mastectomy: 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 70 papers to Dr. Mullinax, published from 2008 to 2025. 2021 was the busiest year, with 6. The most frequent topics are Sarcoma, Lymphocytes, Tumor-Infiltrating and Immunotherapy, Adoptive. Dr. Mullinax has published most often in Ann Surg Oncol. Dr. Mullinax's most frequent co-authors are Ricardo J. Gonzalez, MD, Amod Ashok Sarnaik, MD and Jonathan S. Zager, MD.

Dmand AI links Dr. Mullinax to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Sarcoma, Neoplasms, Connective and Soft Tissue and Hemangiosarcoma. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 2.

CMS Open Payments shows 29 general payments to Dr. Mullinax from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Merit Medical Systems Inc paid the most, $11,369.

Dmand AI lists 1 award for Dr. Mullinax, most recently Resident of the Year in 2013.

Dr. Mullinax graduated from USF Health Morsani College of Medicine in 2007. Dr. Mullinax is a member of AOA, AACR, ACS, AAS and SSO.

Dr. Mullinax is in network with 7 carriers, including Elevance, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.